Letrozole combined with oral contraceptives versus oral contraceptives alone in the treatment of endometriosis-related pain symptoms: a pilot study

Yi Zhao, Zhao Y, Luan X, Xiaofei Luan, Wang Y, Yuya Wang
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2020 · vol. 37(1) , pp. 51–55 · doi:10.1080/09513590.2020.1807502 · PMID:32936010 · W3087196156
RCT OA: closed CC0 ⤵ 13 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This pilot study found that letrozole combined with oral contraceptives significantly decreased endometriosis-related pain symptoms compared to oral contraceptives alone.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: To compare the efficacy and the tolerability of letrozole combined with oral contraceptives versus oral contraceptives alone in treating endometriosis-related pain. METHODS: A total of 820 women with endometriosis presented with endometriosis-related pain were enrolled with this study. Patients were randomly treated either with letrozole (2.5 mg/day) combined with oral contraceptives (Desogestrel and Ethinylestradiol Tablets) or oral contraceptives (Desogestrel and Ethinylestradiol Tablets) alone for 6 months. Changes in pain symptoms during treatment and in 1 months after treatment, 6-month follow-up and 12-month follow-up were evaluated. Adverse effects of each treatment protocol were recorded. RESULTS: At completion of treatment, the intensity of chronic pelvic pain continued to decrease during treatment and at 1-month after treatment it was significantly lower than at 6-month follow-up and baseline level both in LE + oral contraceptives group (Mean ± SD,1.5 ± 1.4) and in oral contraceptives alone group(Mean ± SD,2.9 ± 1.2).The intensity of chronic pelvic pain and deep dyspareunia was significantly decrease at both 1-month after treatment and 6-month follow-up. CONCLUSIONS: This treatment for endometriosis is a promising new modality that warrants further investigation.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_paindyspareunia

MeSH descriptors

Aromatase Inhibitors Contraceptives, Oral, Hormonal Endometriosis Letrozole Pain Adult Adult Aromatase Inhibitors Aromatase Inhibitors Contraceptives, Oral, Hormonal Contraceptives, Oral, Hormonal Desogestrel Desogestrel Desogestrel Drug Therapy, Combination Drug Therapy, Combination Endometriosis Endometriosis Endometriosis Ethinyl Estradiol

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (15)

Cited by (16)

Source provenance

europepmc
last seen: 2026-10-13T06:10:10.580696+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:28:33.187078+00:00
License: CC0 · commercial use OK